DONATE TODAY
May 29, 2019

Rebound of medication abortion in Texas following updated mifepristone label

In 2013, Texas House Bill 2 (HB 2) placed restrictions on the use of medication abortion, which later were nullified with the 2016 FDA-approved mifepristone label.
Share
Facebook
LinkedIn
X

Rebound of medication abortion in Texas following updated mifepristone label

https://doi.org/10.1016/j.contraception.2019.01.001

Details
Date
May 29, 2019
Category
Abortion Care
Journal
The journal Contraception
Authors
Sarah E. Baum, Kari White, Kristine Hopkins, Joseph E. Potter, Daniel Grossman
key findings
Citation
Related Publications

Texas women’s experiences attempting self-induced abortion in the face of dwindling options

The availability of abortion care in Texas has dramatically declined since the introduction of House Bill 2 (HB2), the restrictive
Abortion Care, Research Briefs, Texas

Knowledge of medication abortion among young people in Texas

In 2023, Resound Research for Reproductive Health conducted a statewide survey of 768 Texas participants in Knowledge Panel who were
Abortion Care, Research Briefs, Texas

Mental Distress Among Females Following 2021 Abortion Restrictions in Texas

These findings suggest that Texas’s abortion restrictions were associated with increases in mental distress among females of reproductive age, especially
Abortion Care, Systems of Care, Texas

Why Confidential Contraception Matters for Texas Teens

In many states, adolescents under 18 can consent to their own contraceptive care, but Texas is not one of them.
Contraception, Research Briefs, Systems of Care, Texas

Contact Us

  • 737-381-1260
  • info@resoundrh.org

Advancing equitable reproductive health through rigorous research.

© 2024 Resound Research for Reproductive Health is fiscally sponsored by The Tides Center

PRIVACY POLICY
TERMS OF USE